Evidence map›Paper›PMID 42230420›Full record

ArticleBiological trace element research2026

Subtype-Specific Alterations in Copper Trafficking Associated with KRAS Mutations in Isogenic Colorectal Cancer Cell Lines.

Elina Üveges, Anikó Gaál, Gergely Szakács, Éva Bakos, Christina Streli, Peter Kregsamer, Marcell Baranyi, Balázs Hegedűs, Norbert Szoboszlai

Abstract read
In one paragraph

Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elina ÜvegesIntegrative Health and Environmental Analysis Research Laboratory, Institute of Chemistry, ELTE Eötvös Loránd University, Budapest, Hungary.
Anikó GaálBiological Nanochemistry Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, Budapest, 1117, Hungary.
Gergely SzakácsInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Éva BakosInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Christina StreliInstitute of Atomic and Subatomic Physics, Vienna University of Technology, Vienna, Austria.
Peter KregsamerInstitute of Atomic and Subatomic Physics, Vienna University of Technology, Vienna, Austria.
Marcell BaranyiDepartment of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
Balázs HegedűsDepartment of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary. Balazs.Hegedues@rlk.uk-essen.de.
Norbert SzoboszlaiIntegrative Health and Environmental Analysis Research Laboratory, Institute of Chemistry, ELTE Eötvös Loránd University, Budapest, Hungary. norbert.szoboszlai@ttk.elte.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copper bioavailability has been identified as a potential target for KRAS-mutant colorectal cancer, a disease for which treatment options remain limited. Therefore, we investigated copper homeostasis in isogeneic colorectal cancer cell models carrying distinct KRAS codon 12 mutations (G12C, G12D and G12V). Our results show that copper homeostasis differs among KRAS-mutant cells in a mutation-specific manner, with the greatest change observed in G12V, followed by G12C and then G12D. Specifically, G12V-mutant cells show reduced copper levels, increased copper uptake, reduced intracellular copper levels after prolonged exposure to exogenous copper, reduced sensitivity to copper-induced toxicity, protection against intracellular copper chelators (neocuproine, DpC, Dp44mT), and increased expression of the copper transporter ATP7A. In contrast, G12D mutant cells exhibit minimal differences in copper metabolism compared to controls, while G12C display an intermediate phenotype between the other two mutations. Notably, the copper chelator ammonium tetrathiomolybdate inhibited cell growth in all KRAS-mutant cells. Our results suggest that KRAS-mutant colorectal cancer cells are sensitive to perturbations in copper homeostasis in a mutation subtype-specific manner.

Indexed as

Colorectal NeoplasmsCopperMutationProto-Oncogene Proteins p21(ras)Cell Line, TumorCell ProliferationChelating AgentsHumansMolybdenumChelating AgentsCopperKRAS protein, humanMolybdenumProto-Oncogene Proteins p21(ras)tetrathiomolybdateChelating agentColorectal cancerCopperCopper transporterKRAS mutation

Identifiers

PMID42230420
PMCPMC13437747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.